参麦注射液联合黄芪注射液治疗成人病毒性心肌炎的Meta分析  

Shenmai Injection combining Huangqi Injection for treating adult viral myocarditis:a Meta-analysis

作　　者：王松云[1] 赵劲波[1] 江洪[1] 

机构地区：[1]武汉大学人民医院心血管内科,武汉430060

出　　处：《中国循证心血管医学杂志》2013年第3期237-240,共4页Chinese Journal of Evidence-Based Cardiovascular Medicine

摘　　要：目的系统评价参麦注射液联合黄芪注射液治疗病毒性心肌炎的疗效。方法计算机检索PubMed、CENTRAL、EMbase、the ISI Web of Knowledge databases、VIP、CNKI、CBM和WANFANG数据库中关于参麦注射液联合黄芪注射液对病毒性心肌炎的疗效的随机对照试验(RCTs),对纳入的文献进行严格评价和资料提取,对符合标准的RCTs用RevMan5.1软件进行Meta分析。结果共纳入14篇文献。Meta分析显示:在西医常规治疗基础上联合应用参麦注射液和黄芪注射液组(联合治疗组)在治疗(7～30)天后总有效率明显优于常规治疗组(OR=4.52,95%可信区间:2.80～7.30,P<0.001)。联合治疗组不良反应事件发生率低且轻微。结论常规治疗基础上联用参麦注射液和黄芪注射液治疗病毒性心肌炎可提高总体疗效。但因本研究纳入的原始文献质量偏低,影响了研究结果的论证强度,尚有待开展更多设计合理、执行严格、多中心、大样本且随访时间充分的RCT来进一步验证。Objective To review systematically the curative effect of Shenmai Injection combining Huangqi Injection on adult viral myocarditis. Methods The databases of PubMed, CENTRAL, Embase, the ISI Web of Knowledge Databases, VIP, CNKI, CBM and WanFang Database were retrieved with computer for collecting randomized controlled trials （RCTs） about the curative effect of Shenmai Injection combining Huangqi Injection on adult viral myoearditis. The included RCTs were given strict reviews and the data was extracted. The RCTs that met the criterion were given Meta-analysis by using RevMan5.1 software. Results There were totally 14 RCTs included. The Meta-analysis showed that the total effective rate was significantly higher in combining group （treated with routine therapy of Western medicine combining Shenmai Injection and Huangqi Injection） than that in routine group （treated with routine therapy of Western medicine） after treatment for 7 to 30 days （OR=4.52, 95%CI： 2.80-7.30, P〈0.001）. The occurrence rate of adverse events was lower and the reactions were mild in combining group. Conclusion The routine therapy of Western medicine combining Shenmai Injection and Huangqi Injection has higher curative effect on adult viral myocarditis. Because of the quality of the origin literature included in this study is poor, the intensity of argument in the results is affected. More RCTs with reasonable design, strict performance, multi-center, large scale and sufficient follow-up time are needed for further confirmation.

关 键 词：参麦注射液 黄芪注射液 病毒性心肌炎 META分析 

分 类 号：R4[医药卫生—临床医学]